Immuneering (IMRX) Free Cash Flow (2020 - 2026)
Immuneering (IMRX) recorded quarterly Free Cash Flow of -$18.5 million in Q1 2026, down 85.79% quarter-over-quarter from -$10.0 million in Q4 2025, and down 31.4% on a YoY basis from -$27.0 million in Q1 2025.
Immuneering (IMRX) Free Cash Flow (2020 - 2026) Analysis & Trends
Immuneering's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$18.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 31.4% year-over-year to -$18.5 million; the TTM figure through Mar 2026 stood at -$49.9 million (up 6.96% YoY), while the FY2025 annual figure was -$45.5 million, up 17.42% from the prior year.
- Free Cash Flow was -$18.5 million for Q1 2026 at Immuneering, down from -$10.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$9.4 million in Q2 2025 to a low of -$18.5 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$12.5 million across 5 years, with a median of -$12.0 million in 2025.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow plunged 101.35% in 2022, then surged 31.37% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$11.8 million in 2022, then decreased by 1.08% to -$11.9 million in 2023, then declined by 21.54% to -$14.5 million in 2024, then soared by 31.37% to -$10.0 million in 2025, then tumbled by 85.79% to -$18.5 million in 2026.
- The last three Free Cash Flow figures came in at -$18.5 million (Q1 2026), -$10.0 million (Q4 2025), and -$12.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | -18.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.51 Mn |
| Mar 31, 2026 | -18.51 Mn |
| Dec 31, 2025 | -9.96 Mn |
| Dec 31, 2025 | -9.96 Mn |
| Sep 30, 2025 | -11.98 Mn |
| Sep 30, 2025 | -11.98 Mn |
| Jun 30, 2025 | -9.45 Mn |
| Jun 30, 2025 | -9.45 Mn |
| Mar 31, 2025 | -14.09 Mn |
| Mar 31, 2025 | -14.09 Mn |
| Dec 31, 2024 | -14.52 Mn |
| Dec 31, 2024 | -14.52 Mn |
| Sep 30, 2024 | -13.48 Mn |
| Sep 30, 2024 | -13.48 Mn |
| Jun 30, 2024 | -11.56 Mn |
| Jun 30, 2024 | -11.56 Mn |
| Mar 31, 2024 | -15.53 Mn |
| Mar 31, 2024 | -15.53 Mn |
| Dec 31, 2023 | -11.95 Mn |
| Dec 31, 2023 | -11.95 Mn |